To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

This study tests whether anlotinib — a targeted anti-cancer drug that blocks tumor blood vessel growth — helps prevent cancer recurrence in people with non-small cell lung cancer (NSCLC) who did not achieve complete tumor eradication (called pathological complete response, or pCR) after pre-surgery immunotherapy plus chemotherapy. **You may be eligible if...** - You are 18 or older and have stage IIA–IIIA non-small cell lung cancer - You received pre-surgery treatment combining PD-1/PD-L1 immunotherapy with chemotherapy - You had surgery to completely remove the tumor (R0 resection) - Your tumor was not completely destroyed by the pre-surgery treatment - You are in good general health (ECOG 0 or 1) with an expected survival of at least 3 months **You may NOT be eligible if...** - You achieved complete tumor elimination (pCR) after pre-surgery treatment - You have serious heart, liver, or kidney problems - You have active bleeding or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.